Trending: BPC-157 Research A newly reported 2026 study examined BPC-157 in human internal mammary artery tissue and described endothelium-dependent, nitric-oxide-mediated vasorelaxation. This is a notable translational step because much of the BPC-157 literature has relied on animal or laboratory models.…
Orforglipron explained: how Foundayo, an oral GLP-1 pill, compares with semaglutide and injectable research peptides in 2026.
FDA BPC-157 2026 PCAC explainer: what peptide compounding review means for BPC-157, MOTS-c and TB-500 research.
Cagrilinitide Enters the Research Spotlight Cagrilinitide is emerging as this week’s notable research topic. The compound is drawing attention because it acts through amylin-receptor pathways rather than the GLP-1 pathway alone, creating a useful comparison point for researchers tracking metabolic…
Cagrilinitide research overview: amylin analog mechanisms, comparisons with retatrutide and semaglutide, evidence limits, FAQ.
Retatrutide safety research in 2026: side effects, BMJ death headline context, evidence limits, comparisons, and research-only FAQ.
Research note: This week’s strongest signal is GLP-1 neuroprotection research. A July 11 meta-analysis in Neurological Sciences reviewed glucagon-like peptide-1 receptor agonists in Parkinson’s disease research, adding momentum to the broader GLP-1 brain-health literature. Trending: GLP-1 and Parkinson’s Research The…
GLP-1 Parkinson’s disease research: 2026 meta-analysis, semaglutide neuroprotection, comparisons, evidence limits, and FAQ.
Retatrutide osteoarthritis research: TRIUMPH-1 joint findings, weight-bearing tissue questions, comparisons, evidence limits, and FAQ.
Retatrutide research trends, BPC-157 product highlight, and a study-design tip for peptide literature review.